Home > Cardiology > HFA 2022 > Cardiac contractility modulation therapy promising for patients with HFpEF

Cardiac contractility modulation therapy promising for patients with HFpEF

Presented By
Prof. Cecilia Linde, Karolinska University Hospital, Sweden
Conference
HFA 2022
Trial
CCM-HFpEF
A pilot study assessing cardiac contractility modulation (CCM) therapy in patients with heart failure and preserved ejection fraction (HFpEF) displayed a significant improvement in the health status of patients following this therapy. Further studies are warranted to establish the applicability of CCM in patients with HFpEF. “CCM therapy has demonstrated to be efficacious in patients with HF and reduced or mid-range ejection fractions,” mentioned Prof. Cecilia Linde (Karolinska University Hospital, Sweden) [1]. The current prospective, multicentre CCM-HFpEF pilot study (NCT03240237) aimed to assess the efficacy and safety of CCM in patients with symptomatic HFpEF (n=47). The primary efficacy endpoint was the mean change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score through week 24, whereas the primary safety endpoint was the numbe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on